107 results about "Hematology" patented technology

The invention belongs to the technical field of data processing, and particularly discloses a method and system for predicting the lifetime of a non-small cell lung cancer patient after radiotherapy, and the method comprises the steps: collecting multi-time-point imaging and hematology follow-up visit data of the patient after radiotherapy, building a longitudinal follow-up visit sequence, and mapping the longitudinal follow-up visit sequence to a unified time axis; determining a bimodal first-time significant improvement point through preset rule judgment, and constructing and standardizing an asynchronous index according to the bimodal first-time significant improvement point; then inputting a feature vector at a follow-up time point, encoding a bimodal sequence through a Transform time sequence encoder, and generating joint representation through cross-modal interaction; and finally, inputting the standardized asynchronous index, the joint representation and the clinical and radiotherapy characteristics into a DeepHit model, and outputting a patient survival distribution prediction result. According to the method, bimodal indexes can be accurately captured, time dislocation is improved, prediction accuracy and individualization degree are improved, and a reliable basis is provided for clinical prognosis evaluation.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

Methods and systems for detecting cancer and / or determining a cancer tissue of origin are disclosed. In some embodiments, a multiclass cancer classifier is disclosed that is trained with a plurality of biological samples containing cfDNA fragments. The analytics system derives a feature vector for each sample, and the multiclass classifier predicts a probability likelihood for each of a plurality of tissue of origin (TOO) classes. In some embodiments, the plurality of TOO classes include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples having high tissue signal are pruned from the training sample set. In another embodiment, the analytics system stratifies samples according to tissue signal and applies binary threshold cutoffs determined for each stratum.

The present application relates to a kind of aerosol delivery system toxicology scoring method and storage medium, method includes: setting target group, the test biological of target group is in aerosol exposure environment;Blood physiological index and multi-omics data of control group are obtained, the test biological of control group is in air exposure environment;Blood physiological index of target group is measured, and first toxicology score is determined according to the difference of blood physiological index of target group and control group;Multi-omics data of target group is measured, and second toxicology score is determined according to the difference of multi-omics data of target group and control group;According to first toxicology score and second toxicology score, determine the comprehensive toxicology score of target group;Blood physiological index includes blood biochemistry, coagulation function and hematology index;Multi-omics data includes transcriptomics, proteomics and metabolomics data.The present application is evaluated from macroscopic physiological level and microscopic molecular level by the above setting, the toxicological effect of aerosol such as electronic cigarette liquid etc. is evaluated comprehensively.

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

This invention describes CD33 antibodies and their antigen-binding fragments, as well as CD33 / vδ2 multispecific antibodies or their antigen-binding fragments. The invention also describes polynucleotides encoding these antibodies, compositions comprising these antibodies, methods for producing these antibodies, and methods for treating or preventing diseases such as hematological cancers using these antibodies.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg, anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

A hematology analyzer for analyzing a fluid sample and comprising a frame body defining a first axis (X-X′) and a second axis (Y-Y′), a cartridge unit having a first compartment containing the fluid sample and a second compartment containing a cleaning fluid, a fluid analysis module comprising a first probe and a second probe, a first transmission unit configured to hold and move the cartridge unit along the first axis (X-X′) to align the first compartment and the second compartment with the first probe and the second probe, respectively, and a second transmission unit configured to move the fluid analysis module along the second axis (Y-Y′) such that the first probe and the second probe pierce the first compartment and the second compartment, respectively.

The invention relates to the technical field of medical care, in particular to a hemostasis device for hematology department nursing, which comprises a shell and a hemostasis module, and the shell is provided with a connecting wrist strap; the hemostasis module comprises a pressing block and a limiting ring, a cavity is formed in the pressing block, the cavity is communicated with the outside through a water injection opening, a clamping ring is arranged on the pressing block in a liftable mode, and the clamping ring is connected with an adjusting mechanism; a through hole is formed in the shell, and the hemostasis module body is arranged in the through hole in a penetrating mode and connected with the shell through an elastic piece; the hemostasis device further comprises a locking mechanism, the locking mechanism is arranged in the shell and used for locking the position of the hemostasis module after the hemostasis module is pressed downwards, the locking mechanism comprises a release button, the locking mechanism can automatically lock the position of the hemostasis module after the hemostasis module is pressed downwards, it is ensured that pressure is stable and continuous, and locking can be instantly relieved by pressing the release button. The module can be quickly reset under the action of the elastic piece, and medical staff can control the pressure according to individual differences and bleeding conditions of patients.

The present invention relates to the field of medicine and hematology, and provides compositions and methods for modulating Factor VIII function. In particular, the present invention provides novel factor VIII variants, compositions comprising the variants, nucleic acid molecules encoding the variants, expression vectors comprising the nucleic acid molecules, and host cells comprising the vectors. The present invention also provides methods of using the variants and / or compositions to modulate the coagulation cascade in a patient in need thereof for the treatment of diseases including, but not limited to, hemophilia, particularly hemophilia A.

The utility model discloses a blood cell smear auxiliary device. The blood cell smear auxiliary device comprises a blood filling pool and an adjusting part, the blood filling pool is provided with a containing groove used for containing blood, the groove bottom face of the containing groove is opened to be used for being matched with a glass slide, and the adjusting part comprises a first adjusting piece and a second adjusting piece. The first adjusting piece and the second adjusting piece are oppositely arranged in the blood filling pool, and the first adjusting piece and the second adjusting piece can move so as to adjust the volume of the containing groove. According to the blood cell smear auxiliary device, the preparation efficiency and quality of the blood smear can be remarkably improved, and a more reliable sample is provided for hematological examination, so that the accuracy and efficiency of medical diagnosis are promoted.

The present disclosure discloses methods and systems for detecting cancer and / or determining tissue of origin of cancer. In some embodiments, a multi-classification cancer classifier is disclosed that is trained using a plurality of biological samples containing cfDNA fragments. The analysis system derives a feature vector for each sample, and the multi-classification classifier predicts a probabilistic likelihood for each of a plurality of cancer signal origin (CSO) classifications. In some embodiments, the plurality of CSO classifications include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples with high predictive scores are rejected from a training sample set. In another embodiment, the analysis system stratifies the sample according to a predicted score and applies a binary threshold cutoff value determined for each stratification.

The application relates to the technical field of blood cell separation machines, in particular to a blood cell separation machine device for hematology nursing, which comprises a stirring mechanism, a feeding mechanism, a drawing mechanism, a centrifugal mechanism and a separation mechanism. The upper end of the stirring mechanism is provided with the feeding mechanism, the lower end of the feeding mechanism is provided with the drawing mechanism, the lower end of the drawing mechanism is provided with the centrifugal mechanism, and the centrifugal mechanism is provided with the separation mechanism at one end. The rotating stirring blade can uniformly mix blood and anticoagulant, preventing the blood from coagulating before centrifugation. The second sliding block and the first connecting pipe are in sliding cooperation, so that the anticoagulant can be automatically and quantitatively added into the cylinder. The second sleeve can draw the blood in the cylinder to the test tube when the first motor stops rotating. The sliding pipe and the second fixed block can quickly take out the separated blood plasma. The third sliding block can be pulled outward to take out the remaining blood cells conveniently and quickly.

The invention relates to a sampling device for the hematology department, which comprises a handle body, the handle body is connected with a seat body, the surface of the seat body is provided with a sampling single body which sequentially comprises a fixing piece, a rebounding piece and a sampling part, and the inner side surface of the rebounding piece is provided with the sampling part which sequentially comprises a main section, an arc section and a side section in the longitudinal direction and is of a Y-shaped structure. By arranging the sampling single body of the soft deformation body, pressing force is converted into elastic potential energy, the arc section can generate larger deformation quantity, the elastic potential energy of the sampling part is increased, the elastic potential energy and release of the elastic potential energy are converted into micro-friction force with an ulcer surface, and the arc section is completely released, returned and overturned to generate sliding micro-friction force; fungus attached to the outer side face of the arc section is taken down, the friction force in sampling is reduced while the sampling efficiency is guaranteed through the resilience force and micro friction force combination principle, bleeding caused by too large friction force is limited, and the bleeding risk of leukemia patients is reduced.

A slide imaging device (110) for digital morphology in hematology is disclosed, comprising at least one z-axis stage (112) configured to place a microscope slide (114) at a sample plane, wherein a biological sample may be placed on the microscope slide (114), wherein the z-axis stage (112) is configured to set a relative distance along the optical axis (118) of the slide imaging device (110) between the microscope slide (114) and the imaging system (116) of the slide imaging device (110). The slide imaging apparatus (110) further includes at least one sample beam path and at least one autofocus beam path, the at least one autofocus beam path including at least one pattern illumination source (132), the at least one pattern illumination source including at least one light emitter (134) and at least one grating (136), wherein the grating (136) is tilted relative to the optical axis (118) of the slide imaging apparatus (110), wherein the autofocus beam path includes at least one second transmission system (140) and at least one autofocus camera (138), wherein the second transmission system (140) is configured to allow a pattern generated by the pattern illumination source (132) to be projected onto the sample plane and to allow a pattern reflected from the sample plane to be propagated to the autofocus camera (138), wherein the autofocus camera (138) is configured to generate at least one digital autofocus image of the pattern reflected from the sample plane. The slide imaging apparatus (110) further includes at least one processing unit (148) configured to analyze the digitally autofocused image, wherein the analysis includes spatial analysis of contrast and determination of the image location with maximum contrast. The slide imaging apparatus (110) further includes at least one control unit (150) configured to control the z-axis stage (112) taking into account the determined image location to position the microscope slide (114) along the optical axis (118) of the slide imaging apparatus (110).

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The invention discloses a specialized nurse-oriented blood purification personalized course recommendation method and system, and relates to the technical field of medical teaching. The method comprises the following steps: S1, collecting blood purification operation data, and preprocessing the blood purification operation data; s2, dividing the preprocessed blood purification operation data into four stages, and calculating corresponding operation characteristic values; S3, obtaining operation capability characterization parameters of each stage, constructing a nurse operation evaluation model, and outputting a blood purification operation evaluation value of a nurse; and S4, generating a personalized learning task package based on the hematopurification operation evaluation value and the weight coefficient of each stage, pushing the personalized learning task package to a nurse side, constructing an evaluation difference matrix before and after learning, and performing closed-loop updating of course recommendation. The problem that an existing nurse training system cannot achieve objective evaluation and precise course matching based on multi-dimensional data of the hematology operation process, and consequently learning content is general and insufficient in individuation is solved.

The invention provides a tool for intelligently evaluating the dystrophy risk of a patient with nasopharyngeal carcinoma, and the tool for evaluating the specific dystrophy of nasopharyngeal carcinoma is constructed by integrating indexes such as social demographic data, physique measurement, tumor staging, chemoradiotherapy conditions, recent adverse reactions and hematology indexes, so that high-precision risk evaluation is realized. Through single-factor and multi-factor analysis, the variable weight is optimized, and the discrimination capability and stability of the model are improved. An intelligent applet based on artificial intelligence is developed, patient data are extracted, nutrition risk calculation is completed within seconds, evaluation time is shortened, and clinical working efficiency is improved. The system also has the functions of dynamic monitoring and intelligent early warning, automatically updates the evaluation result along with the treatment progress of the patient, and provides individualized intervention suggestions. The defects that a traditional nutrition evaluation tool is high in subjectivity, low in efficiency, lack of tumor specificity and low in informatization degree are overcome, and an efficient, accurate and automatic intelligent evaluation solution is provided for clinic.

A computer-implemented method for determining states in vivo and in vitro by analyzing blood parameters, including obtaining blood parameters of a blood sample by a hematology analyzer, the blood parameters including quantitative and qualitative measurement variables, and the measurement variables include properties of individual cells, and the individual cells comprise blood cells. The computer-implemented method further includes creating a scatterplot having at least two axes, and each axis of the scatterplot comprises a different measurement variable; and determining an in-vivo and / or in-vitro and / or post-mortem state by a deep learning model and / or a machine learning model. The input variable for the deep learning model includes a scatterplot, and the input variable for the machine learning model includes 1D vector. The 1D vector is created by vectorizing the scatterplot; and automatically generating a report including the result regarding the determination of the state.

According to this invention, there is provided an automated sample preparation system implemented within a disposable cartridge. The system utilizes finger prick blood or venous blood as an input sample and performs various sample processing steps, including fluidic metering, fluidic routing, and reagent storage with an integrated biosensor. The architecture, of this system, enables efficient and accurate testing of blood parameters, hematology parameters such as CBC, CD4-T cells count, but not limited to, Complete Blood Cell Count (CBC) and measurement of biomarkers such as Troponin, IL-6, Procalcitonin, but not limited to, CRP, Procalcitonin, and IL-6 through ELISA and is flexible to implement other electrochemistry techniques.

The invention relates to a device, method and arrangement for treating the waste fluid (1) of a haematological analysis device (2), in particular for reducing or removing contaminants from the waste fluid (1) of a blood count apparatus, comprising: – an inlet (3) for introducing the waste fluid (1), – a filter device (5) disposed downstream of the inlet (3) in the flow direction (4) of the waste fluid (1) and serving to filter the waste fluid (1), – a sterilisation device (6) disposed downstream of the inlet (3) and in particular downstream of the filter device (5) in the flow direction (4) of the waste fluid (1) and serving to at least partially sterilise the waste fluid (1), – an outlet (7) for discharging the treated waste fluid (1).

This invention discloses 6-substituted 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, which are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used to treat a variety of disorders and diseases where inhibition of DHODH may be clinically useful, including cancers such as hematologic cancers, including acute myeloid leukemia (AML), graft-versus-host disease, autoimmune disorders, and disorders associated with T-cell proliferation. When administered orally, the disclosed compounds exhibit flipped kinetics, i.e., pharmacokinetics in which the absorption rate, rather than the elimination rate, dominates the pharmacokinetic profile. The disclosed compounds exhibit sustained pharmacokinetic characteristics rather than immediate release characteristics. This summary is intended as a scanning tool for searching in a specific field and is not intended to limit this disclosure.

1. The name of this design product: Color-coded identification rack for blood sample tubes in hematology. 2. Purpose of this design product: Used in the hematology department to classify, code and place blood sample tubes. 3. The design key point of this appearance design product lies in the combination of shape and color. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA-dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF / CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti-CD19, anti-EGFR, anti-BCMA . . . ) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.

1. The name of the design product: blood coagulation instrument. 2. The use of the design product: for blood test in department of hematology. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

The invention relates to a method and a kit for generating nucleic acid for target capture. The method involves binding of a circ-olio sequence to at least one target oligonucleotide to generate a single stranded circular DNA. The single stranded circular DNA is bidirectionally amplified with the sense and antisense oligonucleotides, followed by biotinylation to obtain for a double-stranded concatemer of linear sequence. The double-stranded concatemer of linear sequence with the restriction endonucleases produces a target capture nucleic acid. The method offers a scalable targeted capture of pr eselected genomic regions, and is cost effective. The method of generating nucleic acid for target capture has application in the field of oncology hematology, inherited malignancies, germline disorders, microbiology and prenatal diagnosis. The invention generates baits over high GC-rich regions of the genome.

The invention relates to a method and a sensor for detecting and / or quantifying a set of hematological parameters in a blood or derived biological fluid sample, the set of hematological parameters comprises at least one parameter selected from the group consisting of the number (RC) of a blood cell component in the blood or derived biological fluid, the average blood cell volume (MCV) of said blood cell component, the percentage (HCT) of the blood cell component in the sample volume and the amount of at least one substance (Hb) comprising a protoporphyrin metal complex. The invention also relates to a method for producing the electrical analysis sensor.

The disclosure features calibration fluids that include a plurality of beads, such as cellulose, silica, poly(methyl-methacrylate) (PMMA), melamine, cross-linked agarose, polyvinylacetate (PVA), and / or polystyrene beads, where the beads are sized and colored to represent at least one type of blood cell; and a carrier fluid, that can include a polymer or polymerizing matrix, e.g., a water-soluble resin, e.g., an acrylic or polyurethane water-soluble resin or a starch or a cellulose, serum, and / or one or more or sugars. The disclosure also features methods of using the calibration fluids to calibrate automated sample preparation systems, such as automated hematology analyzer systems, e.g., image-based hematology analyzer systems.